Pfizer Inc. / ReViral Ltd.

Respiratory Syncytial Virus (RSV) Antiviral Therapy

58K US cases/yr · $12.0B Global RSV market (vaccines + therapeutics) 2030 forecast · 100-300 Annual U.S. pediatric RSV deaths (children <5)

Disease Overview

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection across all ages, with the heaviest disease burden in infants under 1 year and adults over 65. CDC estimates RSV causes 58,000-80,000 pediatric hospitalizations annually in U.S. children under age 5, with approximately 100-300 pediatric deaths per year, plus 60,000-160,000 adult hospitalizations and 6,000-10,000 adult deaths annually in those over 65. The 2022-2023 RSV season set records for pediatric hospitalization rates, accelerating regulatory and commercial interest in both prevention (vaccines, monoclonal antibodies) and treatment (antivirals). The treatment landscape historically has been limited to ribavirin (off-label, narrow use) and supportive care; the prevention landscape transformed in 2023 with FDA approvals for AstraZeneca/Sanofi Beyfortus (nirsevimab) for infants, GSK Arexvy and Pfizer Abrysvo for adults 60+. ReViral's lead asset sisunatovir is an oral RSV fusion inhibitor — addressing the unmet treatment need for hospitalized or high-risk symptomatic RSV patients. The U.S. addressable population for an effective oral antiviral spans ~250,000-500,000 high-risk pediatric, transplant, and immunocompromised patients annually, plus emergency outpatient settings.

Competitive Landscape

The RSV competitive landscape is bifurcated between prevention and treatment. Prevention has rapidly consolidated around Beyfortus (nirsevimab, anti-RSV F monoclonal antibody, AstraZeneca/Sanofi) for infants — approved July 2023 with universal infant ACIP recommendation; Synagis (palivizumab, AstraZeneca) — legacy high-risk infant mAb being displaced; Arexvy (RSVPreF3, GSK) — adult 60+ vaccine approved May 2023; Abrysvo (RSVpreF, Pfizer) — adult 60+ and maternal vaccine approved May/August 2023; mRESVIA (Moderna mRNA-1345) — adult 60+ approved May 2024. Treatment is essentially open territory. ReViral's sisunatovir oral RSV fusion inhibitor competes with very few late-stage rivals — Enanta Pharmaceuticals' EDP-938 (oral RSV N-protein inhibitor, Phase 2b RSVHR mixed results), Janssen's JNJ-53718678 (oral fusion inhibitor, terminated 2022), and Gilead's GS-5806 (presatovir, terminated 2017). The Pfizer acquisition slotted ReViral's antiviral capability inside Pfizer's broader RSV franchise that already includes Abrysvo, allowing prevention plus treatment positioning across the patient pathway. Earlier-stage RSV antivirals include AstraZeneca's RSV antibody pipeline plus several preclinical fusion-inhibitor academic programs and Merck's still-undisclosed RSV early-stage program. The treatment-side competitive moat is the absence of viable late-stage rivals plus Pfizer's commercial leverage on RSV prevention infrastructure, although approval timing remains uncertain after ongoing Phase 2 efficacy reads need to demonstrate clinically meaningful viral load reduction and symptom benefit in vulnerable populations to support pivotal program design.